Skip to main content

Adding Immune Checkpoint Inhibitors to Bladder-Preservation Therapy in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis

In brief

Bladder-preservation studies with immune therapy report 81% complete responses

Across 12 studies involving 335 patients, immune checkpoint inhibitor-containing bladder-preservation treatment was associated with an 81% complete response rate and 80% overall survival at two years. Serious treatment-related side effects occurred in 36%, and the mostly noncomparative, small studies cannot show whether immune therapy improves outcomes over standard treatment; randomized trials are needed.

Journal
Critical reviews in oncology/hematology (Q1)
Published
15 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Reza Ghalehtaki, Alireza Shariati, Ehsan Mehrtabar, Mohammad Reza Arshadi, Taher Fanihagh
PMID
43035127
DOI
10.1016/j.critrevonc.2026.105701

Why clinicians should know about it

  • Picked for Surgical Oncology (top studies of the week, 22 November 2026): Bladder preservation addresses avoiding cystectomy
  • Picked for Radiation Oncology (top studies of the week, 22 November 2026): ICI addition to bladder-preserving radiotherapy shows encouraging activity

Abstract

BACKGROUND AND OBJECTIVE: Trimodality therapy is an established bladder-preserving alternative to radical cystectomy for muscle-invasive bladder cancer (MIBC), but recurrence remains common. Immune checkpoint inhibitors (ICIs) are active in urothelial carcinoma and may enhance radiotherapy-based bladder preservation. We conducted a systematic review and meta-analysis of the efficacy and safety of adding ICIs to curative-intent non-operative treatment for MIBC. METHODS: PubMed, Scopus, and Embase were searched through June 28, 2026. Eligible studies included adults with MIBC receiving bladder-preserving radiotherapy or chemoradiotherapy incorporating an ICI. The review followed PRISMA and was registered in PROSPERO. Outcomes included overall survival (OS), bladder-intact disease-free survival (BIDFS), clinical complete response (cCR), and treatment- and immune-related adverse events (trAEs, irAEs). Proportions were pooled using random-effects models with Hartung-Knapp adjustment. KEY FINDINGS AND LIMITATIONS: Twelve studies comprising 335 patients were included. Pooled OS was 95%, 91%, 80%, and 73% at 6, 12, 24, and 36 months, respectively. Pooled BIDFS was 85% at 6 months and 66% at 24 months. Pooled cCR was 81%, rising to 85% in chemotherapy-containing studies. All-grade and grade ≥3 trAEs occurred in 94% and 36% of patients, while all-grade and grade ≥3 irAEs occurred in 70% and 17%. The evidence was limited by small sample sizes, heterogeneity, and predominantly noncomparative designs. CONCLUSION AND CLINICAL IMPLICATION: ICI-containing radiotherapy-based bladder preservation shows encouraging activity, but incremental benefit over standard therapy remains unproven. Randomized trials, including SWOG/NRG S1806 and KEYNOTE-992, are needed.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.